TOP > 外国特許検索 > Anticancer agent

Anticancer agent NEW

外国特許コード F170009202
整理番号 AF12-12WO
掲載日 2017年9月12日
出願国 欧州特許庁(EPO)
出願番号 13758278
公報番号 2837387
出願日 平成25年3月5日(2013.3.5)
公報発行日 平成27年2月18日(2015.2.18)
国際出願番号 JP2013055927
国際公開番号 WO2013133253
国際出願日 平成25年3月5日(2013.3.5)
国際公開日 平成25年9月12日(2013.9.12)
優先権データ
  • 特願2012-052334 (2012.3.8) JP
  • 2013WO-JP55927 (2013.3.5) WO
発明の名称 (英語) Anticancer agent NEW
発明の概要(英語) (EP2837387)
According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells.
The anticancer agent of the present invention primarily comprises: a human antibody º-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody º-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence.
特許請求の範囲(英語) [claim1]
1. An anticancer agent, comprising: (1) a human antibody kappa -type light chain in the form of a dimer in which a variable region is composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 1, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence; (2) a human antibody kappa -type light chain in the form of a dimer in which a variable region is composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 7, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence; (3) a human antibody kappa -type light chain in the form of a dimer in which a variable region is composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 9, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence; (4) a human antibody kappa -type light chain in the form of a dimer in which a variable region is composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 13, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence; (5) a human antibody kappa -type light chain in the form of a monomer in which a variable region is composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 19, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence; (6) a human antibody kappa -type light chain in the form of a monomer in which a variable region is composed of a polypeptide represented by an amino acid sequence consisting of the 1st to 113th amino acids of SEQ ID NO: 38, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence; (7) a human antibody kappa -type light chain in the form of a dimer in which a variable region is composed of a polypeptide represented by an amino acid sequence consisting of the 1st to 112th amino acids of SEQ ID NO: 40, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence; or (8) a human antibody kappa -type light chain in the form of a dimer in which a variable region is composed of a polypeptide represented by an amino acid sequence consisting of the 1st to 107th amino acids of SEQ ID NO: 41, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence.
[claim2]
2. The anticancer agent according to claim 1, wherein
the human antibody kappa -type light chain of (1) above is a human antibody kappa -type light chain in the form of a dimer composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 2, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence;
the human antibody kappa -type light chain of (2) above is a human antibody kappa -type light chain in the form of a dimer composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 8, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence;
the human antibody kappa -type light chain of (3) above is a human antibody kappa -type light chain in the form of a dimer composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 10, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence;
the human antibody kappa -type light chain of (4) above is a human antibody kappa -type light chain in the form of a dimer composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 14, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence;
the human antibody kappa -type light chain of (5) above is a human antibody kappa -type light chain in the form of a monomer composed of a polypeptide represented by an amino acid sequence in which cysteine at position 219 has been deleted or substituted by an amino acid other than cysteine in the amino acid sequence of SEQ ID NO: 20, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence;
the human antibody kappa -type light chain of (6) above is a human antibody kappa -type light chain in the form of a monomer composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 38, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence;
the human antibody kappa -type light chain of (7) above is a human antibody kappa -type light chain in the form of a dimer composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 40, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence; or
the human antibody kappa -type light chain of (8) above is a human antibody kappa -type light chain in the form of a dimer composed of a polypeptide represented by an amino acid sequence of SEQ ID NO: 41, an amino acid sequence in which one or a plurality of the amino acids in the amino acid sequence have been substituted, added or deleted, or an amino acid sequence having homology of 95% or more with the amino acid sequence.
  • 出願人(英語)
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • UDA TAIZO
  • HIFUMI EMI
国際特許分類(IPC)
指定国 (EP2837387)
Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
参考情報 (研究プロジェクト等) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close